Biodel Inc. (BIOD: Quote) and Aegis Therapeutics LLC announced a partnership providing Biodel an exclusive worldwide license to Aegis' proprietary ProTek and Intravail technologies for the development and commercialization of pharmaceutical formulations of glucagon.
ProTek protein stabilization technology comprises the use of proprietary GRAS excipients that prevent aggregation of proteins and peptides thereby improving the stability of drug product formulated with these excipients.
Intravail comprises a broad class of transmucosal absorption enhancement agents that allow non-invasive systemic delivery of potent peptide, protein, nucleotide-related, and other small and large molecule drugs.
Biodel stated that the agreement will enable the development and commercialization of a wide variety of glucagon presentations, including Biodel's lead glucagon product candidate, a liquid formulation in an auto injector intended for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Other presentations and indications contemplated by the agreement include the use of glucagon in the treatment of hyperinsulinemia with continuous subcutaneous infusion and the treatment of hypoglycemia via intranasal administration and administration via a bi-hormonal pump.
 | | To receive FREE breaking news email alerts for BIODEL INC and others in your portfolio |
|
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
Business News